Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369433 · ClinicalTrials.gov registry record · NA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A NA study, sponsored by AVEO Pharmaceuticals.
- Terminated
- Registry status
- NA
- Development phase
- 225
- Enrollment target
NCT01369433: Clinical Trial NA study, sponsored by AVEO Pharmaceuticals.
NCT01369433 is a NA study that was terminated before completion, run by AVEO Pharmaceuticals. The registered enrollment target is 225 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01369433, a NA study, was terminated before completion, sponsored by AVEO Pharmaceuticals.
- TERMINATED
- Registry status
- NA
- Development phase
- 225 participants
- Enrollment target
Study Summary
Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent) protocol. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the (original) parent protocol. Subjects will be seen by the investigator every 4 weeks (± 5 days). Adverse events and blood pressure will be recorded. At the beginning of Cycle 1 and at the beginning of every odd-numbered cycle (Cycle 3, Cycle 5, etc), clinical laboratory values will be recorded. CT scans to assess disease will be performed at the end of even-numbered cycles (Cycle 2, Cycle 4, etc).
Primary Outcome
Safety and tolerability will be assessed in accordance to the protocol of the parent study in which the subjects had participated, before enrolling in the AV-951-09-901 rollover study.
Interventions
- DRUG Tivozanib
- DRUG Tivozanib (AV-951)
- DRUG Tivozanib + paclitaxel
- DRUG Tivozanib + temsirolimus
- DRUG Tivozanib + capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-10 |
| Phase | NA |
Why NCT01369433 stopped before completion
NCT01369433 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 5 interventions - of which Tivozanib is the first listed.
NCT01369433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01369433 about?
NCT01369433 is a clinical study titled "A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols". Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent)...
What is the current status of trial NCT01369433?
This trial is currently terminated. It is a NA study. The enrollment target is 225 participants. The study started on 2010-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01369433?
The interventions under investigation include: Tivozanib (DRUG), Tivozanib (AV-951) (DRUG), Tivozanib + paclitaxel (DRUG), Tivozanib + temsirolimus (DRUG), Tivozanib + capecitabine (DRUG).
Who is sponsoring clinical trial NCT01369433?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01369433's enrollment target sits among peer trials
225 472nd of 2000 higher than 1,523 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia